SUMMARY Twenty eight patients with severe, intractable spasticity have been treated by chronic intrathecal administration of baclofen. An implantable programmable drug-administration-device (DAD) was used with a permanent intrathecal catheter. Infusion of 50 to 800 ug//day of baclofen completely abolished spasticity. Follow-up was up to two years. Therapeutic effect was documented by clinical assessment of tone, spasms and reflexes and by electrophysiological recordings of monoand polysynaptic reflex activity. Complications and untoward side-effects of the procedure were few. This procedure is recommended for spasticity of spinal origin refractory to physiotherapy and oral medication. It is a preferable alternative to ablative surgical intervention.
After an upper motoneuron lesion in man, a spastic syndrome often develops with a delay of weeks or months. This is characterised by hyperactive monoand polysynaptic reflexes and a velocity dependent increase in muscle tone. Depending on the site of the lesion, the features of the motor disorder can vary considerably. In spinal cord transection the powerful inhibitory action of the vestibulo-spinal pathway ( projecting from the lateral vestibular nucleus) on the tonic innervation offlexors is eliminated, leading to an increase in flexor muscle tone of the legs. Lesions of the reticulo-spinal pathways cause loss of inhibition of the flexion reflex, resulting in spontaneous and sometimes painful flexor spasms. On the other hand, extensor spasms can also occur. All these patients suffer frequently from severe disability having their legs in a fixed, usually flexed, position causing nursing problems and severe handicap in daily life.
Flexor spasticity is often resistant to drugs in tolerable doses. Microsurgical procedures like selective peripheral neurotomy, posterior rhizotomy' and longitudinal myelotomy have been used. These interventions are designed to interrupt the spinal reflex arc or to reduce the afferent input to the dorsal horn.
Serious neurologic deficits such as bladder dysfunction, increasing paresis or sensory loss may occur and partial recurrence of the original symptoms are common. Therefore a non-destructive approach is preferable. In some cases spinal stimulation may provide a moderate amelioration of spasticity, particularly with regard to bladder function2 whereas cerebellar stimulation has proven to be ineffective in the long term.3
Baclofen (f- [4-chlorophenyl] -GABA, Lioresal), introduced as oral antispastic drug, is a gammaamino-butyric-acid (GABA)-anologue that selectively acts on the GABA-B-receptor.4 GABA itself is ineffective, because it does not penetrate the blood-brainbarrier in sufficient amounts.5 Its action on supraspinal and spinal cord synapses is inhibitory.6 Baclofen is a lipophilic GABA mimetic drug. It 25 We present the results of a multi-centre study conducted at four independent hospitals in four European countries following identical investigational protocols and using the same, programmable DAD for intrathecal application of baclofen as treatment of spasticity.
Materials and methods
The study was Prior to implantation the device was filled with 10-12 ml of the drug in a low concentration, usually 500 pg/ml (delivered by Ciba Geigy Corp, Basel, Switzerland). The flow was started shortly after implantation and the patient's individual need ofdosage could usually be determined within 3 to 5 days postoperatively. Refills were performed by a percutaneous puncture through a rubber septum in the pump device with intervals ranging between 20 to 90 days, although even longer intervals would have been possible in some cases.
Since the implantation of a medical device in the human body carries an increased risk of infection, most patients received prophylactic antibiotics the day of the implantation (prior to surgery) and up to 3 days thereafter. The only pump pocket infection occurred in one of the first patients who did not receive prophylactic antibiotics. Follow-up: The effect of treatment was quantified by clinical ratings, using the Ashworth-scale for muscle tone assessment and rating scales for frequency and severity of spontaneous spasms and strength of tendon reflexes. The patients were evaluated during the hospital stay and thereafter at monthly intervals, later every second month or at the time of refilling the pump. Re-programming with checking of pump function was performed on the same occasions. Those suffering from painful spasms due to an incomplete spinal lesion became free ofpain. To avoid venous stasis in the legs, the drug was titrated to allow some spontaneous spasms. The reduction of spontaneous spasms developed in parallel with a decreased hypereflexic activity of the bladder, resulting in less frequent voiding. In a patient (no. I 1) who had a DCS previously implanted for extremely severe extensor spasms it was found that stimulation and DAD baclofen infusion had additive effects. She used stimulation to inhibit temporary spells of spasms and to supplement the effects of baclofen the required dose of which could thus be minimised. Changes in dosage: Once individual dose requirements were met and muscle tone was stabilised, the patients were discharged from the ward. However, in a considerable number of patients an increase of dose was necessary to maintain the initial therapeutic effect. This tendency to drug tolerance varied considerably, as did the individual dose requirements (see table and fig 2) . Usually the increase of dosage, to retain the therapeutic effect, became evident during the first 3 months. Dose increase varied between 5% and 500%. Later on, stable conditions were reached in most cases. Some patients experienced an increasing number of spasms even after one year, often as the first sign of tolerance. Electrophysiologic data: Recordings of flexion reflex and ankle clonus were performed in a subgroup of the patients prior to treatment, after bolus injection or during the stable phase of drug treatment. Rectified EMG recordings prior to treatment and with continuous infusion of baclofen 235 pg/day are presented in Another pump had to be removed because of a pocket infection 3 days after implantation and replaced 2 months later; this patient has been doing well during the last 12 months. All other pumps worked without any problems.
In two patients the catheter had to be replaced owing to dislocation shortly after implantation. In subsequent cases this problem was overcome by advancing the catheter tip 10 cm more rostrally in the subarachoid space. One catheter, inserted under total anaesthesia, had to be replaced because it irritated a sacral root and caused radicular pain. The pain disappeared after correction of the catheter position. All subsequent operations were performed under spinal anaesthesia to avoid root irritation in the awake patient. In one patient the tip of the catheter was blocked after about 4 months and had to be exchanged. Side effects of the drug: Unwanted side effects were rare and tolerable. Some patients complained of slight fatigue or sleepiness, mainly after the test bolus injection or in the beginning of the therapy. By slow, stepwise changes of the dose this problem could be avoided.
Some patients became more aware of their degree of paresis, when tone became reduced as a result of the treatment. Thus those patients who previously were able to walk as a result of an increased extensor tone, had trouble standing up. Also weakness in the upper extremities became apparent occasionally, in particular when the catheter was placed higher than at a mid-thoracic level. In particular, this often occurred in multiple sclerosis patients who also suffered from minor latent paresis or moderate spasticity in the arms.
In two patients concomitant self-medication, while on continuous intrathecal baclofen, caused reversible coma and respiratory depression making admission to the intensive-care unit necessary. Patient no. 3, already suffering from severe brainstem lesions due to multiple sclerosis with bulbar signs and occasional respiratory irregularities, had to be intubated because of respiratory depression. It was not known whether she had taken 80 or even 100 mg of baclofen by mouth or sleeping pills in addition. Furthermore, a deterioration of the underlying disease (multiple sclerosis) might have contributed. She woke up within 36 hours and returned to a normal state. Patient no. 21, suffering from terminal renal insufficiency took 60 mg/day of oral baclofen and became comatose. He was back to normal within 36 hours, followed by a baclofen withdrawal-induced psychosis. Concomitant oral medication should therefore be discontinued or carefully controlled by the physician. Tolerance: Tolerance to baclofen was not a serious problem. Only in patient no. 4 was a 500% increase of the dose necessary. After about four months the patient again complained of progressive spontaneous painful spasms. Since opioids are known to be effective for spasticity (and pain),'8 265-3-5 mg/day morphine were administered by the drug pump instead of baclofen. There was good relief of spasticity for the following 1 to 2 weeks, but then signs of tolerance to this drug also became apparent. Baclofen was therefore again instituted and proved to be effective.
Discussion
It must be emphasised that only the pain due to the muscle spasms could be influenced by the baclofen treatment. The deafferentation pain remained completely unaffected corresponding to the completely different pathophysiology of this pain type. Tolerance: One reason why an excessively high dose of baclofen was required in this particular patient might be due to the fact that the CSF circulation was hindered by a block at the site of the traumatic spinal cord compression not allowing redistribution in CSF. Thus the effect was mediated only by pure physical diffusion of the compound. As a rule, intrathecal baclofen is not recommended when abnormal CSF circulation is present. Overdose: Since no pharmacological antagonist is available for baclofen to date, the problem ofoverdose is of major importance. Recently the cholinergic compound physostigmine has been shown to have antagonistic properties in case of overdose. In animal experiments physostigmine 0-1 mg/kg i.v. maintained respiratory rate when given at 30 minute intervals to dogs that had received 50-400 pg of baclofen intracisternally." In three patients who suffered from respiratory depression after an accidental bolus injection of 80-800 pg baclofen intrathecally, 2 mg ofphysostigmine i.v. reversed the respiratory depression and somnolence within minutes. In one case a second injection of 2 mg was necessary.28 In animal experiments high doses of baclofen directly depress medullary inspiratory neurons, whereas low doses increase respiratory activity by disinhibition of medullary neurons.
Since the rostral spread of the drug presumably is insufficient, it may be hypothesised that the cerebral GABA-receptors are very sensitive in patients who are on intrathecal baclofen. The oral doses used prior to implantation are therefore often too high, resulting in serious overdose problems in case of uncontrolled intake. Follow-up requirements: Patients should be carefully
